ESPR Stock Recent News
ESPR LATEST HEADLINES
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website.
ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment for patients with hypercholesterolemia. The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan.
Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism. The company's Q1 showed accelerating revenue growth, but guidance offered little new information. A lipid lurker marketing campaign shows early top of the funnel success, but there is little data yet to demonstrate bottom funnel performance.
Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to loss of $0.79 per share a year ago.
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website.
Esperion Therapeutics (ESPR) specializes in cholesterol lowering medications. President and CEO Sheldon Koenig joins Nicole Petallides to give an overview of the company.
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?